When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT) , two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period. However, while investors are supposed to buy low, even at current levels, Editas Medicine and Sarepta aren't attractive stocks to buy.
Let's consider why investors should stay a safe distance away from these two biotech companies.